FREEDOM Trial: A Plain-English Overview of What It Established

By
Published Updated Last reviewed
Clinical medical image for trials freedom: FREEDOM Trial: A Plain-English Overview of What It Established

At a glance

| Field | Detail | |-------|--------| | Trial name | FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) | | N | 7,868 postmenopausal women | | Intervention | Denosumab 60 mg subcutaneous every 6 months | | Comparator | Placebo (matching subcutaneous injection) | | Duration | 36 months | | Primary endpoint | New morphometric vertebral fractures at 36 months | | Key result | Relative risk reduction of 68% (2.3% vs 7.2%; RR 0.32 to 95% CI 0.26-0.41) |

The Question FREEDOM Asked

Before 2009, bisphosphonates dominated osteoporosis treatment. They worked, but compliance was abysmal. Weekly or monthly oral pills that required fasting, upright posture, and precise timing led to adherence rates below 50% at one year. Denosumab offered something different: a monoclonal antibody against RANK ligand, delivered as a subcutaneous shot every six months. The FREEDOM trial asked whether this biologic mechanism and simpler dosing schedule actually prevented fractures.

The study was not a head-to-head comparison against bisphosphonates. It was a placebo-controlled efficacy trial designed to secure FDA approval. That distinction matters when interpreting what it proved.

Who Was Enrolled

Investigators recruited 7,868 women between ages 60 and 90 (mean age 72.3) across 214 centers in North America, Europe, Latin America, and Australasia. All were at least 5 years past menopause. Bone mineral density T-scores at the lumbar spine or total hip had to fall between -2.5 and -4.0, placing participants in the established osteoporosis range.

Key exclusions: women currently on bisphosphonates or other osteoporosis drugs, those with severe vitamin D deficiency (<12 ng/mL), and anyone with conditions affecting bone metabolism beyond postmenopausal loss. All participants received daily calcium (at least 1 to 000 mg) and vitamin D (at least 400 IU) supplementation regardless of group assignment.

This population was narrower than real-world clinical practice. The trial excluded women with very low T-scores (below -4.0), those with prevalent vertebral fractures numbering more than four, and anyone who had used potent antiresorptives. The results therefore apply most cleanly to moderate-severity postmenopausal osteoporosis.

What They Were Given

Randomization split participants 1:1. The active group received 60 mg denosumab subcutaneously every 6 months (seven injections total over 36 months). The control group received matching placebo injections on the same schedule.

Neither patients nor investigators knew which injection was real. Compliance was high: over 93% of participants received all scheduled doses, a figure that far exceeds typical bisphosphonate persistence in observational data.

What Was Measured

The primary endpoint was the incidence of new morphometric vertebral fractures over 36 months. Lateral spine radiographs were taken at baseline, 12, 24, and 36 months and read centrally using the Genant semiquantitative method. A new fracture required at least a 20% reduction in vertebral height plus a minimum 4 mm absolute decrease.

Prespecified secondary endpoints included:

  • Time to first nonvertebral fracture
  • Time to first hip fracture
  • Change in bone mineral density at lumbar spine, total hip, and femoral neck

The Results in Detail

Vertebral Fractures (Primary Endpoint)

| Timepoint | Denosumab | Placebo | Relative Risk Reduction | |-----------|-----------|---------|------------------------| | 0-12 months | 0.9% | 2.2% | 61% | | 0-24 months | 1.4% | 5.0% | 71% | | 0-36 months | 2.3% | 7.2% | 68% (p < 0.001) |

The number needed to treat (NNT) to prevent one vertebral fracture over three years was approximately 21. For context, that is comparable to alendronate's NNT from the FIT trial.

Nonvertebral and Hip Fractures

Denosumab reduced nonvertebral fractures by 20% (6.5% vs 8.0%; HR 0.80 to 95% CI 0.67-0.95, p = 0.01). Hip fractures fell by 40% (0.7% vs 1.2%; HR 0.60 to 95% CI 0.37-0.97, p = 0.04).

The hip fracture result met statistical significance, but barely. With only 88 total hip fractures across both groups, the confidence interval stretches close to 1.0. This is important: for an individual patient asking "will this protect my hip specifically?", the evidence is suggestive but less definitive than for vertebral protection.

Bone Mineral Density

BMD gains were consistent and progressive across all measured sites:

| Site | 12-month gain | 36-month gain | |------|---------------|---------------| | Lumbar spine | +3.0% | +9.2% | | Total hip | +1.4% | +6.0% | | Femoral neck | +1.4% | +4.8% |

These BMD increases exceeded those typically seen with oral bisphosphonates at equivalent timepoints, though the clinical significance of BMD differences between drugs remains debated.

Safety Profile From the Trial

Adverse events were balanced between groups overall. Rates of cancer, cardiovascular events, and serious infections did not differ meaningfully. Specific findings worth noting:

  • Eczema: 3.0% denosumab vs 1.7% placebo (the only adverse event with a clear signal)
  • Cellulitis: 0.3% vs <0.1% (rare but a known class concern with RANKL inhibition)
  • Hypocalcemia: No clinically significant cases, though all participants were calcium/vitamin D supplemented
  • Osteonecrosis of the jaw: Zero cases in either group during the 3-year trial

The absence of ONJ in FREEDOM does not mean it does not occur with denosumab. Post-marketing surveillance and the long-term extension have since documented cases, particularly in patients receiving higher oncology doses. The FDA label for Prolia now carries warnings for both ONJ and atypical femoral fractures.

Methodological Strengths

FREEDOM was well-designed for a registration trial. Blinding was rigorous. Vertebral fracture assessment used centralized radiology reads, removing site-to-site variability. The sample size (nearly 8,000) gave adequate power for fracture endpoints rather than relying solely on BMD as a surrogate. Follow-up was 36 months, longer than many antiresorptive trials that rely on 12-month surrogate data.

Completion rate was 83%, meaning most randomized women contributed full follow-up data.

Limitations the Authors Acknowledged

The original publication noted several constraints:

  1. Placebo comparison only. FREEDOM did not test whether denosumab outperforms bisphosphonates. For that question, you need different trials.
  2. Population homogeneity. Predominantly white, postmenopausal women without recent fracture history. Generalizability to men, premenopausal women, or glucocorticoid-induced osteoporosis requires separate data.
  3. Calcium/vitamin D co-treatment. All participants received supplements, making it impossible to separate denosumab's fracture benefit from baseline nutritional optimization.
  4. No assessment of fracture after discontinuation. This became critically important later, when post-marketing data revealed rebound vertebral fractures after stopping denosumab.

What Happened After FREEDOM

The open-label extension continued for up to 10 years total. Women originally on denosumab kept gaining BMD (lumbar spine +21.7% at year 10). Those crossing over from placebo showed catch-up gains. Long-term safety remained broadly consistent with the original trial.

However, the extension also revealed that stopping denosumab triggers rapid bone loss, returning BMD to baseline within 1-2 years. More concerning, a subset of discontinuers experienced multiple vertebral fractures in quick succession. Current Endocrine Society guidelines now recommend transitioning to a bisphosphonate before or immediately after stopping denosumab to prevent rebound.

What It Means for Clinical Practice Today

FREEDOM established three things that shape prescribing in 2026:

First, denosumab works. A 68% vertebral fracture reduction is clinically meaningful and statistically strong. It earned FDA approval in 2010 and guideline recommendations from the American Association of Clinical Endocrinology and the Endocrine Society.

Second, the twice-yearly injection schedule offers a compliance advantage. For patients who cannot tolerate or adhere to oral bisphosphonates, denosumab provides an alternative route with demonstrated fracture prevention.

Third, denosumab is not a drug you start casually. The rebound risk on discontinuation means clinicians must plan an exit strategy before the first injection. This was not apparent from FREEDOM alone but became clear from its extension and post-marketing data.

For the average postmenopausal woman with a T-score between -2.5 and -4.0 who resembles the FREEDOM population, denosumab remains a well-supported first-line choice, provided she understands the commitment to ongoing treatment or a structured transition plan.

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References

  1. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-765. PubMed
  2. U.S. Food and Drug Administration. Prolia (denosumab) prescribing information. Revised 2020. FDA Label
  3. Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513-523. PubMed
  4. Tsourdi E, Langdahl B, Cohen-Solal M, et al. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 2017;105:11-17. PubMed
  5. Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595-1622. PubMed